生命科学资讯

Regeneron makes $150M bet on Tessera's rare disease gene writing prospect

European Union teams up with Angelini to funnel €150M to European health startups

Belite Bio aims for first approval of Stargardt disease treatment with Phase 3 success

UK agrees to boost drug prices to dodge US pharma tariffs

Appointments and advancements for Dec. 1, 2025

Financings for Dec. 1, 2025

In the clinic for Dec. 1, 2025

Other news to note for Dec. 1, 2025

Regulatory actions for Dec. 1, 2025

Regeneron inks gene editing deal with startup Tessera

Microsize, Schedio link to buy Lonza’s Swiss micronization plant - Fierce Pharma

Study Compares Performance of Emerging Droplet-Based scRNA-seq Platforms to 10x Genomics System - geneonline.com

UK to spend more on medicines for US tariff exemption

Inspecting Bulk Peanuts - AZoM

Belite brings FDA filing into view with phase 3 Stargardt disease victory

GE HealthCare, Philips, Siemens spotlight AI-forward imaging at RSNA 2025

Researchers find chronic stress you can see using a CT scan

Akebia to pay $12M to Q32 Bio for centerpiece of rare kidney disease pipeline

Angelini, European Investment Bank join forces; Radiopharma startup raises $40M

Comparative Study of Two Innovative Single-Cell RNA Platforms - Bioengineer.org